81805-53-0

Basic information

• Product Name: Benzenemethanol, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-
• CAS NO: 81805-53-0
• Molecular Formula: C14H24O2Si
• Molecular Weight: 252.429
• Mol File: 81805-53-0.mol

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-(81805-53-0)
• EPA Substance Registry System: Benzenemethanol, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-(81805-53-0)

Safety Data

• Hazardous Substances Data: 81805-53-0(Hazardous Substances Data)

Usage

General Description

Benzenemethanol, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]- is a chemical compound with a complex structure. It contains a benzene ring attached to a methanol group, as well as a tert-butyl and dimethylsilyl groups connected to an oxygen atom. Benzenemethanol, 3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]- is often used in the synthesis of organic compounds and as a reagent in various chemical reactions. It may also have applications in the field of pharmaceuticals or as a building block for more complex molecules. Overall, this chemical has potential uses in a variety of industries and research fields due to its unique structure and properties.

Upstream product

• 626-18-6 1,3-dimethanol benzene 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 288-32-4 1H-imidazole 
• 18173-64-3 tert-butyldimethylsilanol 

Downstream Products

• 1026659-81-3 tert-Butyl-(3-iodomethyl-benzyloxy)-dimethyl-silane 
• 81168-11-8 3-(((tert-butyldimethylsilyl)oxy)methyl)benzaldehyde 
• 412353-10-7 2-benzyloxycarbonylamino-3-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-propionic acid methyl ester 
• 412353-11-8 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-(3-hydroxymethyl-phenyl)-propionic acid methyl ester 
• 412353-17-4 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-propionic acid methyl ester 
• 412353-13-0 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-[3-(piperazine-1-carbonyl)-phenyl]-propionic acid methyl ester 
• 412353-18-5 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-{3-[(S)-1-diethylcarbamoyl-2-(4-hydroxy-phenyl)-ethylcarbamoyl]-phenyl}-propionic acid methyl ester 
• 160694-15-5 [3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-pyridin-3-yl-methanone 
• 213620-90-7 (E)-7-[3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 213620-92-9 (Z)-7-[3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 198132-20-6 [3-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-pyridin-3-yl-methanol 

Relevant articles and documents

Diverted Total Synthesis of Carolacton-Inspired Analogs Yields Three Distinct Phenotypes in Streptococcus mutans Biofilms

The oral microbiome is a dynamic environment inhabited by both commensals and pathogens. Among these is Streptococcus mutans, the causative agent of dental caries, the most prevalent childhood disease. Carolacton has remarkably specific activity against S. mutans, causing acid-mediated cell death during biofilm formation; however, its complex structure limits its utility. Herein, we report the diverted total synthesis and biological evaluation of a rationally designed library of simplified analogs that unveiled three unique biofilm phenotypes further validating the role of natural product synthesis in the discovery of new biological phenomena.

Galantamine-curcumin hybrids as dual-site binding acetylcholinesterase inhibitors

Galantamine (GAL) and curcumin (CU) are alkaloids used to improve symptomatically neurodegenerative conditions like Alzheimer's disease (AD). GAL acts mainly as an inhibitor of the enzyme acetylcholinesterase (AChE). CU binds to amyloid-beta (Aβ) oligomers and inhibits the formation of Aβ plaques. Here, we combine GAL core with CU fragments and design a combinatorial library of GAL-CU hybrids as dual-site binding AChE inhibitors. The designed hybrids are screened for optimal ADME properties and BBB permeability and docked on AChE. The 14 best performing compounds are synthesized and tested in vitro for neurotoxicity and anti-AChE activity. Five of them are less toxic than GAL and CU and show activities between 41 and 186 times higher than GAL.

EP4 antagonists number

We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

CLPX INHIBITORY COMPOUNDS FOR THE TREATMENT OF MULTI RESISTANT STAPHYLOCOCCUS AUREUS VIRULENCE AND FOR THE TREATMENT OF LEUKEMIA

The present invention relates to antibiotic compounds and their use as ClpX inhibitors and in the treatment of bacterial infections, such as infections with multi-resistant Staphylococcus aureas, and in the treatment of leukemia. The present invention fur

A Chemical Disruptor of the ClpX Chaperone Complex Attenuates the Virulence of Multidrug-Resistant Staphylococcus aureus

The Staphylococcus aureus ClpXP protease is an important regulator of cell homeostasis and virulence. We utilized a high-throughput screen against the ClpXP complex and identified a specific inhibitor of the ClpX chaperone that disrupts its oligomeric sta

6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Novel HIV reverse transcriptase inhibitors

The invention is related to compounds of Formula (I), (II), or (III): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

NOVEL HETEROARYL DERIVATIVE

A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. wherein the ring Z is an optionally substituted heteroaryl, W4 is a single bond, lower alkylene, etc., Ar2 is an optionally substituted aryl, etc., W3 is a single bond, lower alkylene, etc., Ar1 is an optionally substituted arylene, etc., each of W1 and W2 is an optionally substituted lower alkylene, etc., and R1 is carboxyl, an alkoxycarbonyl.

NOVEL HETEROARYL DERIVATIVE

A compound of the following formula (1), or its prodrug or pharmaceutically acceptable salt thereof, being useful as a diabetic medicine or preventive, or blood sugar regulator, or therapeutic agent for hyperlipemia, etc. (1) wherein: the ring Z is an optionally substituted heteroaryl, W4 is a single bond, lower alkylene, etc., Ar2 is an optionally substituted aryl, etc., W3 is a single bond, lower alkylene, etc., Ar1 is an optionally substituted arylene, etc., each of W1 and W2 is an optionally substituted lower alkylene, etc., and R1 is carboxyl, an alkoxycarbonyl, etc.

TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN

The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders - such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α2δ-1 subunit of Ca channels.